CNS drug delivery breakthroughs unlock significant biotech market opportunities

The human brain remains one of the most protected and most difficult to treat organs in the body. Central to this problem is the blood-brain barrier (BBB), a biological defence mechanism that blocks the majority of therapeutics from reaching the central nervous system (CNS). As cases of Alzheimer’s disease climb worldwide and governments sharpen their focus on biodefence readiness, the failure to get drugs to the brain effectively is becoming a critical chokepoint in modern medicine.

Against this backdrop, forward-thinking companies, among them Oncotelic Therapeutics, are contributing to a wider industry move toward advanced delivery platforms built to circumvent traditional barriers and enable rapid, targeted brain access. Oncotelic’s approach features a proprietary intranasal nose-to-brain (N2B) system for fast therapeutic delivery, reflecting a growing acknowledgement that solving CNS delivery, not just drug discovery, may be the key to the next wave of treatments. Oncotelic sits alongside a number of leading biopharma companies including Biogen, Moderna, CytoDyn and Northwest Biotherapeutics.

The blood-brain barrier challenge

The BBB is a highly selective membrane that shields the brain from toxins and pathogens in the bloodstream. While vital for survival, it also poses a significant obstacle to therapeutic development, limiting the passage of most compounds and permitting only select molecules to enter brain tissue. Roughly 98% of small-molecule drugs and nearly all biologics fail to penetrate it effectively, making CNS drug delivery one of the most enduring challenges in pharmaceutical development. Promising compounds frequently fall short not through lack of efficacy, but simply because they cannot reach their targets.

This spans conditions including Alzheimer’s disease, Parkinson’s disease and brain cancers, where treatment options remain scarce despite decades of research and enormous financial investment.

Oncotelic recently announced the completion of a strategic monetisation with Lunai Bioworks, with the transfer agreement covering its N2B delivery system and establishing a joint initiative around biodefence and Alzheimer’s disease.

“Under the terms of the agreement, Oncotelic has granted Lunai Bioworks worldwide rights to the N2B delivery system IP portfolio within defined fields, specifically biodefense medical countermeasures and Alzheimer’s disease only. The company continues to evaluate additional partnerships to further monetize its portfolio while maintaining strategic control over core assets.”

By placing delivery mechanisms on an equal footing with therapeutic development, the company is positioning itself within a broader shift toward integrated solutions tackling one of the most fundamental challenges in CNS medicine.

---

---

Related Topics and Keywords

biotech market opportunities, CNS, Moderna